Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827751 | 1.00 | CYP3A4 (0.62) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL1739571 | 1.00 | CYP3A4 (0.62) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL31545549 | 0.99 | CYP3A4 (0.61) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL31166209 | 0.88 | ALDH1A1 (0.48) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL5305466 | 0.88 | ALDH1A1 (0.48) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| Tenamfetamine SCHEMBL9102083 | 0.83 | TAAR1 (0.57) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL2350405 | 0.83 | CYP3A4 (0.59) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL29827277 | 0.83 | CYP3A4 (0.59) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 | |
| SCHEMBL9781426 | 0.81 | CYP3A4 (0.69) | CYP3A4ALDH1A1SMN1; SMN2MEN1KMT2A | |
| Tenamfetamine SCHEMBL9102090 | 0.80 | SLC6A4 (0.53) | CYP3A4ALDH1A1SMN1; SMN2TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 762 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4366729-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | Arcadia Medicine, Inc. (US) | 2024-05-15 | — | — | EP | claimed |
| EP-4346788-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | Arcadia Medicine, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-111056953-B | Process for the preparation of diamines and polyamines of the diphenylmethane series | 科思创德国股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| CN-116016069-A | Modulation recognition system based on transfer learning | 中国人民解放军国防科技大学 | 2023-04-25 | — | — | CN | claimed |
| EP-3749298-B1 | INHALABLE DRY POWDER CYTIDINE ANALOGUE COMPOSITION AND METHOD OF USE AS A TREATMENT FOR CANCER | LOVELACE BIOMEDICAL RES INSTITUTE (US) | 2023-04-05 | — | — | EP | claimed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | claimed |
| CN-101055589-A | Embedded database storage management method | UNIV BEI HANG (CN) | 2007-10-17 | — | — | CN | claimed |
| EP-1776097-A1 | METHODS OF TREATING OPHTHALMIC CONDITIONS | Allergan, Inc. (US) | 2007-04-25 | — | — | EP | claimed |
| WO-2006103188-A1 | MMDI AND PMDI PRODUCTION BY MEANS OF GAS PHASE PHOSGENATION | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-05 | — | — | WO | claimed |
| WO-2006103189-A1 | MDI PRODUCTION BY MEANS OF LIQUID PHASE AND GAS PHASE PHOSGENATION | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-05 | — | — | WO | claimed |
| WO-2006028798-A2 | METHOD AND SYSTEM FOR FUNDS MANAGEMENT | UBS FINANCIAL SERVICES, INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060047593-A1 | Method and system for funds management | UBS FINANCIAL SERVICES INC. (US) | 2006-03-02 | — | — | US | claimed |
| WO-2006017748-A2 | MATERIALS AND METHODS FOR IDENTIFYING ANTI-SCHIZOPHRENIC AGENTS | DECODE GENETICS EHF. (IS) | 2006-02-16 | — | — | WO | claimed |
| WO-2006015075-A1 | METHODS OF TREATING OPHTHALMIC CONDITIONS | ALLERGAN, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-6697635-B2 | Method and apparatus for forward and reverse power control in mobile telecommunication system | HYUNDAI ELECTRONICS INDUSTRIES CO., LTD. (KR) | 2004-02-24 | — | — | US | claimed |
| US-20010006898-A1 | Method and apparatus for forward and reverse power control in mobile telecommunication system | HYUNDAI ELECTRONICS INDUSTRIES CO., LTD. | 2001-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CYP3A4 2096/4885ALDH1A1 1406/4885SMN1; SMN2 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.